Abstract
The mutagenic activity of razoxane (ICRF 159) was studied using the Salmonella/microsome assay and rodent bone-marrow micronucleus and metaphase assays. Razoxane (up to 5000 micrograms/plate) did not cause an increase in the mutation frequency in the Salmonella/microsome assay. In the mouse micronucleus assay razoxane (200 and 400 mg kg-1 i.p.) was cytotoxic to the bone marrow cells (which limited the analysis) but an increase in micronucleated polychromatic erythrocytes was observed in razoxane dosed animals (5-fold compared to control value). In the Chinese hamster metaphase assay razoxane (up to 500 mg kg-1 orally) induced abnormal chromosome condensation and an increase in structural chromosome aberrations (7 fold compared to control value) as well as an increase in the number of polypoid cells (8-fold compared to control value). The mutagenic effect of razoxane was restricted to eukaryotic organisms and was associated with specific chromosomal changes.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ames B. N., Mccann J., Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res. 1975 Dec;31(6):347–364. doi: 10.1016/0165-1161(75)90046-1. [DOI] [PubMed] [Google Scholar]
- Bakowski M. T. ICRF 159, (+/-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane. Cancer Treat Rev. 1976 Jun;3(2):95–107. doi: 10.1016/s0305-7372(76)80007-2. [DOI] [PubMed] [Google Scholar]
- Creighton A. M., Hellmann K., Whitecross S. Antitumour activity in a series of bisdiketopiperazines. Nature. 1969 Apr 26;222(5191):384–385. doi: 10.1038/222384a0. [DOI] [PubMed] [Google Scholar]
- Dawson K. M. Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. Biochem Pharmacol. 1975 Dec 15;24(24):2249–2253. doi: 10.1016/0006-2952(75)90262-2. [DOI] [PubMed] [Google Scholar]
- Herman E. H., Witiak D. T., Hellmann K., Waravdekar V. S. Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds. Adv Pharmacol Chemother. 1982;19:249–290. doi: 10.1016/s1054-3589(08)60025-3. [DOI] [PubMed] [Google Scholar]
- Schmid W., Arakaki D. T., Breslau N. A., Culbertson J. C. Chemical mutagenesis. The Chinese hamster bone marrow as an in vivo test system. I. Cytogenetic results on basic aspects of the methodology, obtained with alkylating agents. Humangenetik. 1971;11(2):103–118. doi: 10.1007/BF00393791. [DOI] [PubMed] [Google Scholar]
- Sharpe H. B., Field E. O., Hellmann K. Mode of action of the cytostatic agent "ICRF 159". Nature. 1970 May 9;226(5245):524–526. doi: 10.1038/226524a0. [DOI] [PubMed] [Google Scholar]
- Witiak D. T., Lee H. J., Hart R. W., Gibson R. E. Study of trans-cyclopropylbis (diketopiperazine) and chelating agents related to ICRF 159. Cytotoxicity, mutagenicity, and effects on scheduled and unscheduled DNA synthesis. J Med Chem. 1977 May;20(5):630–635. doi: 10.1021/jm00215a003. [DOI] [PubMed] [Google Scholar]